Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature

Table 2 Treatment details for cohort with anorectal melanoma (n = 24)

	Treatment
Primary operation, n	WE	15 (62.5)
	APR	2 (8.3)
	Biopsy alone	7 (29.2)
Primary nodal operation, n	SLNB	6 (25.0)
	CLND	3 (12.5)
	None	15 (62.5)
Adjuvant therapy, n1	Chemotherapy alone	0 (0)
	Radiation alone	1 (4.2)
	Interferon alone	3 (12.5)
	Checkpoint Inhibitor	3 (12.5)
	Combination chemotherapy/radiation	2 (8.3)
	Combination chemotherapy/immunotherapy	3 (12.5)
	Combination radiation/immunotherapy	1 (4.2)
	None	11 (45.8)
Surgery at recurrence2	APR	1 (9.1)
	WE	1 (9.1)
Non-operative therapies at recurrence2	Chemotherapy	1 (9.1)
	Radiation	0 (0)
	Interferon	0 (0)
	Checkpoint Inhibitor	2 (18.2)
	Combination chemotherapy/radiation	4 (26.7)
	Combination chemotherapy/immunotherapy	2 (13.3)
	Combination radiation/immunotherapy	2 (13.3)

¹Excluding patients with distant disease at diagnosis (n = 4).

²Percentages calculated from total patients with recurrence who underwent treatment (n = 8).

APR: Abdominoperineal resection; WE: Wide excision; SLNB: Sentinel lymph node biopsy; CLND: Completion lymph node dissection.